Brief: Landmark Bio to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
06/11/2023 12:46
Nov 6 (Reuters) - Galapagos NV GLPG.AS :
* LANDMARK BIO SIGNS MULTI-YEAR AGREEMENT TO MANUFACTURE
GALAPAGOS' ONCOLOGY CAR-T CELL THERAPY CLINICAL PROGRAMS AT THE
POINT-OF-CARE
* LANDMARK BIO- FINANCIAL TERMS OF AGREEMENT WERE NOT
DISCLOSED
Source text for Eikon: ID:nPnbF0PW5a
Further company coverage: GLPG.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors